Sprash Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-12-2024
- Paid Up Capital ₹ 0.10 M
as on 24-12-2024
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 107.37%
(FY 2020)
- Profit 91.80%
(FY 2020)
- Ebitda 95.97%
(FY 2020)
- Net Worth -5.29%
(FY 2020)
- Total Assets 62.63%
(FY 2020)
About Sprash Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Parmeshwar Lambud, Dattatraya Walaskar, Manisha Lambud, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24233MH2013PTC249883
- Company No.
249883
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Nov 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Sprash Pharmaceutical Private Limited offer?
Sprash Pharmaceutical Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Pain Balm & Ointments.
Who are the key members and board of directors at Sprash Pharmaceutical?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parmeshwar Lambud  | Managing Director | 07-Nov-2013 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dattatraya Walaskar | Director | 07-Nov-2013 | Current |
| Manisha Lambud | Director | 07-Nov-2013 | Current |
| Radha Walaskar | Director | 07-Nov-2013 | Current |
| Vijaya Lambud | Director | 07-Nov-2013 | Current |
Financial Performance of Sprash Pharmaceutical.
Sprash Pharmaceutical Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 107.37% increase. The company also saw a substantial improvement in profitability, with a 91.8% increase in profit. The company's net worth dipped by a decrease of 5.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sprash Pharmaceutical?
In 2020, Sprash Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Mauli Nagari Sah. Nidhi LimitedActive 3 years 10 months
Dattatraya Walaskar and Radha Walaskar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sprash Pharmaceutical?
Unlock and access historical data on people associated with Sprash Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sprash Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sprash Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
